Lupin, Natco Launch Bosentan Tablets in US With 180-Day Exclusivity
Mumbai: Global pharma major Lupin Limited on Wednesday announced the launch of Bosentan Tablets for Oral Suspension, 32 mg in the United States, with 180-day generic drug exclusivity.
The launch follows approval received by Lupin’s alliance partner Natco Pharma Ltd, which holds the exclusive first-to-file status for the product’s Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (USFDA).
Bosentan Tablets for Oral Suspension, 32 mg, are the generic equivalent of Tracleer® Tablets for Oral Suspension of Actelion Pharmaceuticals US, Inc. The drug is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH, to improve pulmonary vascular resistance (PVR) and thereby enhance exercise ability.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.